As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
17 Analysts have issued a Autolus Therapeutics plc forecast:
17 Analysts have issued a Autolus Therapeutics plc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 51 51 |
407%
407%
|
|
| Gross Profit | -31 -31 |
-
|
|
| EBITDA | -265 -265 |
89%
89%
|
|
| EBIT (Operating Income) EBIT | -274 -274 |
86%
86%
|
|
| Net Profit | -225 -225 |
6%
6%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
| Head office | United Kingdom |
| CEO | Christian Itin |
| Employees | 649 |
| Founded | 2014 |
| Website | www.autolus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


